

Supplemental Table for:  
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma  
Ryan Sullivan et al.

**Table S1.** Patient characteristics.

Characteristic	Center			
	MGH (N=120)		Vanderbilt (N=134)	
	N	%	N	%
<b>Gender</b>				
Female	46	38.3	52	38.8
Male	74	61.7	82	61.2
<b>Education</b>				
High school	21	17.5	35	26.1
Vocational/Some college	2	1.7	8	6.0
College graduate/Graduate school	65	54.2	52	38.8
Less than high school graduate	2	1.7	9	6.7
Unknown/Missing	30	25.0	30	22.4
<b>Insurance</b>				
Government	50	41.7	45	33.6
Private	67	55.8	83	61.9
Self pay	3	2.5	1	0.7
Unknown	-	-	5	3.7
<b>Relationship status</b>				
Divorced	8	6.7	12	9.0
Married	90	75.0	100	74.6
Single	14	11.7	15	11.2
Unknown	-	-	1	0.7
Widowed	8	6.7	6	4.5
<b>Employment</b>				
Disabled	4	3.3	8	6.0
Employed	67	55.8	61	45.5
Retired	44	36.7	52	38.8
Unemployed	2	1.7	10	7.5
Unknown	3	2.5	3	2.2
<b>ECOG PS</b>				
0	77	64.2	44	32.8
1	16	13.3	82	61.2
2 or 3	4	3.3	7	5.2
Missing	23	19.2	1	0.7
<b>BRAF Mutation</b>				
Yes	24	20.0	35	26.1
No/Unknown	96	80.0	99	73.9
<b>Melanoma Type</b>				
Acral	4	3.3	8	6.0
Cutaneous	90	75.0	99	73.9
Mucosal	6	5.0	5	3.7
Unknown	9	7.5	18	13.4
Uveal	11	9.2	4	3.0
<b>Received anti-PD-1 therapy</b>	109	90.8	126	94.0

Supplemental Table for:  
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma  
Ryan Sullivan et al.

Characteristic	Center			
	MGH (N=120)		Vanderbilt (N=134)	
	N	%	N	%
<b>Received anti-PD-L1 therapy</b>	11	9.2	8	6.0
<b>Ipi before PD-1</b>				
No	67	55.8	58	43.3
Yes	53	44.2	76	56.7
<b>Ipi after PD-1</b>				
No	94	78.3	117	87.3
Yes	25	20.8	17	12.7
During	1	0.8	-	-
<b>Brain mets</b>				
No	108	90.0	100	74.6
Yes	12	10.0	34	25.4
<b>Liver mets</b>				
No	98	81.7	83	61.9
Yes	22	18.3	51	38.1
<b>LDH-mean (SD)</b>	304.1 (495.7)		333.3 (416.5)	
<b>CCI-mean (SD)</b>	4.3 (2.4)		4.9 (2.3)	
<b>Line of therapy – mean (SD)</b>	1.5 (0.8)		2.4 (1.1)	

Notable differences between centers for the following:

Chi-squared tests: Education,  $p=0.02$ ; ECOG PS,  $p < 0.0001$ ; brain mets,  $p=0.002$ ; liver mets,  $p=0.0005$ .

Wilcoxon rank-sum tests: CCI,  $p=0.03$ ; line of therapy,  $p < 0.0001$ .